vTv Therapeutics Inc (VTVT) FinancialsVTVTvTv Therapeutics Inc

Evaluating the bottom line, vTv Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 25.33%, while the net margin is 30.08%. These profitability ratios, combined with a Return on Equity (ROE) of -11.69%, provide a clear picture of how effectively VTVT converts its operational activities into shareholder value.

In the context of the broader market, VTVT competes directly with industry leaders such as VANI and NRXP. With a market capitalization of $94.92M, it holds a significant position in the sector. When comparing efficiency, VTVT's gross margin of 100.00% stands against VANI's N/A and NRXP's 32.70%. Such benchmarking helps identify whether vTv Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has shown volatility in its earnings, with a recent Q1 EPS of 1.65, but a significant miss in Q2 with -1.05. The gross margin is strong at 100% in Q1 and Q2 of 2026, indicating potential for profitability if revenue stabilizes.